ArticleCardiovascular diabetology2023
Predictive value of high sensitivity C-reactive protein in three-vessel disease patients with and without type 2 diabetes.
Article in Cardiovascular diabetology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 17 citations in OpenAlex.
- Trial
- Advances in the application of frailty scoring in the diagnosis and management of elderly patients with multiple myeloma (Review).Oncology reports · 2026Review
- Inflammation and Cardiovascular Risk: A Systematic Review of High-Sensitivity CRP as a Prognostic Indicator.Cureus · 2026Review
- Development and evaluation of a nutrient-derived anti-inflammatory dietary index (NADI) among Chinese adults.European journal of nutrition · 2026Article
- Cumulative average remnant cholesterol inflammatory index and risk of cardiometabolic multimorbidity: evidence from a prospective nationwide cohort study in China.Lipids in health and disease · 2026Article
- C-Reactive Protein-Albumin-Lymphocyte Index as a Predictor of All-Cause and Cardiovascular Mortality in Individuals With Diabetes or Prediabetes: A National Population-Based Cohort Study.International journal of endocrinology · 2026Article
- Human beta defensins 3 and 6 serve as diagnostic tools for identifying sepsis and pneumonia.Frontiers in immunology · 2026Article
- Joint trajectories of adiposity and systemic inflammation and incident diabetes among older adults: a bi-cohort prospective study with mediation analysis.Frontiers in nutrition · 2026Article
- Can Clinical Biomarkers Guide Optimal Therapeutic Selection in Type 2 Diabetes Mellitus? A Scoping Review.Current atherosclerosis reports · 2025Article
- Elevated inflammation supra-additively promotes the progression from prediabetes to diabetes: a prospective cohort study.Journal of global health · 2025Article
- The role of inflammatory biomarkers RBP4, Lipocalin-2, and hsCRP in prediabetes and type 2 diabetes mellitus.Journal of medical biochemistry · 2025Article
- The Pathogenic Role of C-Reactive Protein in Diabetes-Linked Unstable Atherosclerosis.International journal of molecular sciences · 2025Review
- Linking high-sensitivity C-reactive protein and dyslipidemia among patients with type 2 diabetes mellitus.Bioinformation · 2025Article
- Prognostic Impact of Metabolic and Inflammatory Risk for Periprocedural MI and Long-Term Events in Three-Vessel Disease Patients.Journal of inflammation research · 2025Article
- Hs-CRP, Diabetic Status, and Adverse Events Among Patients Receiving Statin Therapy Following PCI-A Prospective Registry-Based Study.Journal of inflammation research · 2025Article
- Prognostic Value of Fibrinogen-to-Albumin Ratio in Coronary Three-Vessel Disease.Journal of inflammation research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetes mellitus (DM) and atherosclerosis are multifactorial conditions and share a common inflammatory basis. Three-vessel disease (TVD) represents a major challenge for coronary intervention. Nonetheless, the predictive value of high-sensitivity C-reactive protein (hs-CRP) for TVD patients with or without type 2 DM remains unknown. Herein, we aimed to ascertain the long-term predictive value of hs-CRP in TVD patients according to type 2 DM status from a large cohort.
methodsA total of 2734 TVD patients with (n = 1040, 38%) and without (n = 1694, 62%) type 2 diabetes were stratified based on the hs-CRP (< 2 mg/L vs. ≥ 2 mg/L). Three multivariable analysis models were performed to evaluate the effect of potential confounders on the relationship between hs-CRP level and clinical outcomes. The Concordance index, net reclassification improvement (NRI), and integrated discrimination improvement (IDI) were calculated to assess the added effect of hs-CRP and the baseline model with established risk factors on the discrimination of clinical outcomes. The primary endpoint was major adverse cardiac and cerebrovascular events (MACCE).
resultsThe median follow-up duration was 2.4 years. Multivariate Cox regression analyses showed that the incidence of MACCE (adjusted hazard ratio [HR] 1.17, 95% confidence interval [CI] 1.01-1.35, p = 0.031) and all-cause death (HR 1.82, 95% CI 1.07-3.11, p = 0.026) were significantly higher in the diabetic group compared to the non-diabetic group. In the diabetic group, the incidence of MACCE (adjusted HR 1.51, 95% CI 1.09-2.10, p = 0.013) was significantly higher in the high hs-CRP group than in the low hs-CRP group; no significant difference was found for all-cause death (HR 1.63; 95% CI 0.58-4.58, p = 0.349). In the non-diabetic group, the prevalence of MACCE (adjusted HR 0.93, 95% CI 0.71-1.22, p = 0.613) was comparable between the two groups. Finally, the NRI (0.2074, p = 0.001) and IDI (0.0086, p = 0.003) for MACCE were also significantly increased after hs-CRP was added to the baseline model in the diabetic group.
conclusionsElevated hs-CRP is an independent prognostic factor for long-term outcomes of MACCE in TVD patients with type 2 diabetes but not in those without type 2 diabetes. Compared to traditional risk factors, hs-CRP improved the risk prediction of adverse cardiovascular events in TVD patients with type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.